Differential effects of oxyntomodulin and GLP-1 on glucose metabolism

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 2, 2012, Pages

  Du, Xiaobing ^a   Kosinski, Jennifer R ^a   Lao, Julie ^a   Shen, Xiaolan ^a   Petrov, Aleksandr ^a   Chicchi, Gary G ^a   Eiermann, George J ^a   Pocai, Alessandro ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glucagon receptor; Glucagon like peptide 1; Glucose metabolism

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; INSULIN; OXYNTOMODULIN;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HORMONE ACTION; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN; MALE; MICE; MICE, INBRED C57BL; OXYNTOMODULIN; RECEPTORS, GLUCAGON;

EID: 84863953711     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00142.2012     Document Type: Article

References (28)

1. Baggio L, Kieffer TJ, Drucker DJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141: 3703-3709, 2000.
2. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546-558, 2004.
3. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21: 151-166, 1988.
4. Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer X, Ronnett GV, Tan TM, Weigle DS. The obesity epidemic: pharmacological challenges. Mol Interv 8: 82-98, 2008.
5. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244-4250, 2001.
6. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687-2695, 2004.
7. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1: 22-31, 2005.
8. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250, 2008.
9. Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, Henquin JC, Drucker DJ, Schuit F. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48: 1979-1986, 1999.
10. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100: 1438-1443, 2003.
11. Gros L, Demirpence E, Jarrousse C, Kervran A, Bataille D. Characterization of binding sites for oxyntomodulin on a somatostatin-secreting cell line (RIN T3). Endocrinology 130: 1263-1270, 1992.
12. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-E678, 2003.
13. Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul Pept 31: 41-52, 1990.
14. Knop FK, Vilsboll T, Larsen S, Madsbad S, Holst JJ, Krarup T. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care 26: 2581-2587, 2003.
15. Kosinski JR, Hubert J, Carrington PE, Chicchi GG, Mu J, Miller C, Cao J, Bianchi E, Pessi A, Sinharoy R, Marsh DJ, Pocai A. The glucagon receptor is involved in mediating the body weight lowering effects of oxyntomodulin. Obesity 2012 Mar 16. doi: 10.1038/oby.2012.67.
16. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 149: 5670-5678, 2008.
17. McGarry J, Wright PH, Foster DW. Hormonal control of ketogenesis. Rapid activation of hepatic ketogenic capacity in fed rats by anti-insulin serum and glucagon. J Clin Invest 55: 1202-1209, 1975.
18. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47: 66-72, 1998.
19. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661, 1993.
20. Parlevliet ET, Heijboer AC, Schroder-van der Elst JP, Havekes LM, Romijn JA, Pijl H, Corssmit EP. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 294: E142-E147, 2008.
21. -/- mice. Diabetes 47: 1046-1052, 1998.
22. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Glucagonlike peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258-2266, 2009.
23. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
24. Sorensen H, Winzell MS, Brand CL, Fosgerau K, Gelling RW, Nishimura E, Ahren B. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55: 3463-3469, 2006.
25. Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol 292: R962-R970, 2007.
26. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30: 1729-1736, 2006.
27. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54: 2390-2395, 2005.
28. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278: 22418-22423, 2003.